SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

🔥 COCK Token – The Ultimate Cross-Chain MemeFi Powerhouse 🔥  In just under 20 days, $COCK has smashed expectations, broken ATHs, and built a project that’s shaking up Cardano and the entire crypto space. 🐓 What Makes $COCK Special?      The Name: Love it or hate it, the energy and engagement it generates are undeniable. The nuance in language and wild appeal set us apart.     #MEMEFI Pioneer: We’re not just another meme coin. $COCK is leading a movement by combining DeFi mechanics, game theory, and community engagement into a groundbreaking ecosystem.     COCKARENA: At the core of our ecosystem is the COCKARENA, a PvP HODL game. Players battle it out, and early exit fees fuel redistributions, burns, and the treasury. This ensures price appreciation and long-term sustainability for loyal holders.  🎰 The COCK Casino  Our casino isn’t just fun—it’s a serious revenue stream for the FLOCK.      Games: Bonanza, Crash, Blackjack, and Roulette (coming soon!).     Impact: Over 7,834 ADA in profits generated within days, directly supporting rewards, burns, and reinvestment.  💰 COCK-ARENA Loans  Unlock liquidity without selling your tokens.      Loan Terms: Borrow up to 30% of your holdings while continuing to earn rewards in the arena.     Investor Focus: Perfect for savvy investors staying in the game while tapping into their holdings.  🤝 Our Insane Partnerships  We’re bridging gaps, building alliances, and breaking barriers across the crypto space. Key Partners:      DANZO: Powering #MEMEFI with Arena, Casino, and Loans.     KLENEK: Interactive training room.     HSKN (Charles Hoskilien): Supporting and starting COCKPIN with 115 AIR NODES for DePIN aggregation. Plans to add APEX and Earth Nodes through a crypto company incorporated in Costa Rica.     ELITE CATS / SNEKKIES / HOT / BANK: Rewarding NFT holders with COCK-LOCK tokens and vice versa.     OCKZ: COCKSOCKS, Golden Cock Ticket (1M COCK), airdrop rewards, and whitelist perks for holders of 200 ADA worth of $COCK.     OLI Partnership:         Content Creation: Lux and the team are crafting engaging educational content about memes and MemeFi for OLi's platform.         Strategic Investment: The OLi Community Trust will invest in $COCK, distributing 100% of rewards to $OLI holders.         Community Reach: Over 22,000 learners will discover $COCK through OLi's gamified ecosystem.     Hi-Rez the Rapper: Expanding reach in marketing and entertainment.     KUNO, CALEB, CADEN, FITY, ROVER, WhaleInsider: Influential collaborators driving crypto adoption and growth.     Cardano Girls: Helping us understand and communicate effectively with ADA’s female audience.     WallStreetBets: Breaking barriers and increasing engagement.     Antonio Brown: Endorsing, supporting, and even playing in the casino and arena!     Advisors:         BERIS, HECKTHESNEK, RTB, CRYPTOGENIUS: Trusted names advising and supporting the project.  Future Partnerships:  More collaborations are in the pipeline to continue expanding engagement and bring new eyes to ADA and CNTs. 🔥 Unmatched Results in Just 20 Days      Supply Burned: 1.65%, worth 148K ADA!     Arena Fees Collected: 54M COCK, worth over 500K ADA, fueling rewards, burns, and partnerships.     Staked COCK-LOCK: 11M COCK-LOCK in the liquid staking platform, with more coming.     Casino Revenue: Skyrocketing profits directly rewarding holders and growing the treasury.     Top Blast Contests: Generated over 120K ADA in volume, rewarding participants with over 50K ADA in prizes.  🌍 Our Vision  To be the most decentralized, rewarding, and innovative token on Cardano while fostering cross-chain collaboration and onboarding the masses.      Breaking Barriers: We’re bringing BTC, ETH, SOL, and other chains into the fold.     Community-Driven: Focused on building bridges and showcasing that crypto can be fun, rewarding, and sustainable.     Expansion: This is just the beginning. With more burns, rewards, and partnerships on the way, $COCK is set to redefine what’s possible in the MemeFi space.  💎 Time in the arena &gt; Timing the market. The FLOCK is unstoppable. Let’s keep breaking walls for Cardano and onboard new users as we take $COCK to new heights.

CockCardano

COCK CRYPTO is buzzing with community excitement driven by its unique blend of meme culture and real-world utility, notably through its CockyWings LLC chicken wing business. Discussions among "the Flock" highlight multiple revenue streams, passive income opportunities from liquid staking, and the new Memes Hub DAPP, all contributing to a bullish outlook for this prominent Cardano meme asset. This active engagement around its innovative approach and growth potential keeps it trending.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is trending with significant community optimism following the start of a new year, driving discussions around its potential for future performance. Many users are highlighting historical chart patterns and expectations of substantial multi-year growth, often referring to LTC as "digital silver" within the crypto ecosystem. Conversations are centered on accumulation strategies and the potential for a strong market cycle ahead.

Cardano is a blockchain platform built on academic research that enables smart contracts and decentralized applications while using significantly less energy than traditional cryptocurrencies like Bitcoin.   What sets Cardano apart is its methodical, research-driven approach — every major feature is peer-reviewed by scientists and cryptographers before being added to the network. This careful process aims to create a more secure and stable foundation compared to platforms that prioritize speed over thorough testing. The platform's native cryptocurrency, ADA, is used to send money, pay transaction fees, and participate in network governance.  Cardano uses a proof-of-stake system to process transactions, which works differently from Bitcoin's mining approach. Instead of competing to solve complex puzzles, users can "stake" their ADA — essentially locking it up temporarily — to become validators who verify transactions. The system selects validators based on how much ADA they've staked and for how long, then rewards them with additional ADA for their participation. This approach uses far less energy than traditional mining while keeping the network secure. The platform also features a two-layer design that separates basic payment transactions from smart contract operations, allowing each function to be optimized independently for better performance.   ADA holders can earn staking rewards by locking up their tokens to help secure the network, vote on proposed changes to the platform, and use ADA for international money transfers with lower fees than traditional services.  Cardano was founded in 2017 by Charles Hoskinson, who previously helped create Ethereum. Hoskinson leads Input Output Global (IOG), the technology company that builds and maintains Cardano's core software. The ecosystem operates through three organizations: IOG handles technical development, the Cardano Foundation promotes adoption and standardization, and Emurgo helps businesses integrate blockchain technology into their operations. This structure distributes responsibilities across multiple groups rather than concentrating control in a single entity.   In February 2025, major asset manager Grayscale Investments filed to create an exchange-traded fund (ETF) for Cardano with the U.S. Securities and Exchange Commission, which would allow traditional investors to buy ADA through their regular brokerage accounts without needing to set up cryptocurrency wallets.Retry

Cardano

Cardano is trending amid intense community discussion, largely fueled by the burgeoning meme coin "$COCK" which is generating buzz with claims of real-world utility and on-chain liquidity. This viral activity, however, is juxtaposed with widespread frustration and deep skepticism among many Cardano holders, who are lamenting recent price action, calling the asset a "scam," and directing pointed criticism at its founder. The polarized sentiment reflects a market grappling with significant dips and constant comparisons to other altcoins, leaving many questioning ADA's near-term outlook.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is currently a focal point of intense community chatter, largely fueled by a prominent influencer's widely discussed predictions for a substantial price increase as the year concludes. This is set against a backdrop of increasing institutional interest through ETFs, although upcoming token unlocks and regulatory developments are also key talking points.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is generating highly polarized community discussion as the new year begins, with much conversation around anticipated market movements following speculated year-end tax loss selling. Loyal "Diamond Hands" are expressing strong hopes for future pumps and significant appreciation, while a frustrated segment views it as a "scam coin" and laments past losses, questioning its investment value. The broader sentiment reflects a tug-of-war between fervent optimism for 2026 and deep skepticism about its prospects.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy (MSTR) is experiencing heightened investor debate as it faces a potential exclusion from MSCI indices by January 15th, which could trigger significant institutional selling. The community is sharply divided, with many criticizing Michael Saylor's strategy of ongoing share dilution to acquire Bitcoin as a "Ponzi scheme," while others view the stock as deeply undervalued. This polarization is fueled by MSTR's underperformance against Bitcoin and broader speculation about an impending "crypto winter."

Grayscale Investments LLC - Grayscale Bitcoin Trust

Grayscale Bitcoin Trust

Grayscale Bitcoin Trust (GBTC) is trending amidst sharply divided community sentiment regarding Bitcoin's immediate future. A vocal bearish camp anticipates a severe 'crypto winter' and significant price depreciation based on historical four-year cycles and recent ETF outflows. Conversely, bullish investors view current price action as a buying opportunity, emphasizing Bitcoin's underlying strength and the potential for a 'parabolic' rally, while dismissing fears of manipulation.

Unusual Machines, Inc. is a development stage technology company, which engages in the provision of drone solutions with a focus on first-person view (FPV) technology. It offers products to entertainment, recreation, and competitive racing industries. The company was founded on July 11, 2019, and is headquartered in Orlando, FL.

Unusual Machines Inc

Unusual Machines, Inc.

Unusual Machines is trending due to heightened expectations for its US-made drone components, fueled by anticipated restrictions on foreign-produced parts and recent positive financial performance. Community discussions emphasize UMAC's strategic role in providing NDAA-compliant solutions for growing defense programs, including large-scale government initiatives. This positioning is seen as critical for strengthening the domestic drone supply chain within a rapidly expanding sector.

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Tempus AI Inc. - Ordinary Shares - Class A

Tempus AI Inc

Tempus AI is trending after its recent earnings report, where the company achieved its first positive adjusted EBITDA and raised full-year guidance, yet experienced a significant market sell-off, sparking community discussions around a "sell the news" reaction and potential manipulation. Despite this volatility, investors remain divided, with some viewing it as overvalued while others emphasize its unique AI-driven data moat and long-term growth potential in precision medicine, keenly watching for a rebound from key technical support levels.

Silvercorp Metals, Inc. engages in the acquisition, exploration, development, and mining of mineral properties and Environmental, Social and Governance practices. It operates through Mining and Administrative segments. The Mining segment includes Henan Luoning, Guangdong, and others. Its products include Silverbearing lead and Zinc Concentrates.The Administrative segment focuses on Vancouver and Beijing. The company was founded by Rui Feng on October 31, 1991 and is headquartered in Vancouver, Canada.

Silvercorp Metals Inc

Silvercorp Metals Inc.

Silvercorp Metals Inc. ($SVM) is trending following strong Q2 fiscal 2026 financial results and significant revenue growth, coupled with advancing development of its El Domo project. The community is actively debating its potential for a "squeeze" as a key silver miner, fueled by a broader bullish sentiment in the precious metals sector. Many view $SVM as an undervalued play poised for substantial gains if silver prices maintain their upward trajectory.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SELLAS Life Sciences Group (NASDAQ:SLS) Shares Gap Up - What's Next?

SELLAS Life Sciences Group (NASDAQ:SLS) Shares Gap Up - Still a Buy...

<ul class="summary-bullets"><li>The company said that 72 out of the prespecified 80 deaths required to trigger the final analysis have now occurred as of Dec. 26, 2025.</li><li>That extended survival timeline may delay the anticipated year-end 2025 reporting, but could indicate positive treatment impact if unblinded data confirms it.</li><li>The REGAL trial’s final scrutiny depends on reaching the event threshold.</li></ul>SELLAS Life Sciences Group Inc.’s (SLS) shares were in the spotlight on Wednesday after Maxim took an optimistic position regarding the Phase 3 clinical trial of galinpepimut-S (GPS) for acute myeloid leukemia (AML).&nbsp;The study’s contract research organization has informed the company that 72 out of the prespecified 80 patient deaths required to trigger the final analysis have now occurred as of Dec. 26, 2025.<h2 class="st-heading-2">Implications Of Delayed Trigger</h2>Maxim analyst Jason McCarthy noted that&nbsp;because the trial is event-driven rather than time-driven, slower accrual of deaths can simply reflect longer patient survival, a positive sign for the effectiveness of GPS.&nbsp;That extended survival timeline may delay the anticipated year-end 2025 reporting but could indicate positive treatment impact if unblinded data confirms it, added the firm.&nbsp;<a href="https://stocktwits.com/symbol/SLS">SELLAS Life Sciences’ stock</a> traded over 4% higher on Wednesday mid-morning. On Stocktwits, retail sentiment around the stock remained in ‘extremely bullish’ territory amid ‘extremely high’ message volume levels.&nbsp;<figure class="image"><img style="aspect-ratio:941/109;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_31_105329_png_6820d21893.webp" alt="SLS’s Sentiment Meter and Message Volume as of 10:40 a.m. ET on Dec. 31, 2025 | Source: Stocktwits" width="941" height="109"><figcaption>SLS’s Sentiment Meter and Message Volume as of 10:40 a.m. ET on Dec. 31, 2025 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">Event-Driven Analysis</h2>The ongoing GPS trial is an overall survival study, and the final analysis is expected once 80 deaths have occurred.&nbsp;“We appreciate the continued dedication of the patients, families, and investigators participating in the pivotal Phase 3 REGAL trial where survival times, fortunately for patients and caregivers, appear longer than expected,” said SELLAS CEO Angelos Stergiou on Monday. “While the 80th event has not yet occurred, and we remain fully blinded, every passing month may increase the probability of a successful study as highlighted by key opinion leaders in our recent R&amp;D event.”GPS is SELLAS’ main drug candidate, and it works by targeting the WT1 protein found in many different cancers. The company is currently evaluating the drug as a potential maintenance therapy in patients with Acute Myeloid Leukemia who have achieved complete remission following second-line salvage therapy.SLS stock has gained over 234% year-to-date.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dan-ives-says-eightco-is-emerging-as-core-human-authentication-layer-of-digital-economy/cL7BOaURECc">Dan Ives Says Eightco Is Emerging As Core Human Authentication Layer Of Digital Economy</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Why Is SLS Stock Drawing Significant Investor Attention Today?

Maxim analyst Jason McCarthy noted that because the trial is event-driven rather than time-driven, slower accrual of deaths can simply reflect longer patient survival, a positive sign for the effectiveness of GPS. 

Equity

Maxim analyst Jason McCarthy noted that because the trial is event-driven rather than time-driven, slower accrual of deaths can simply reflect longer patient survival, a positive sign for the effectiveness of GPS. 


SELLAS Life Sciences Group (NASDAQ:SLS) Sets New 52-Week High - Here's What Happened

SELLAS Life Sciences Group (NASDAQ:SLS) Hits New 12-Month High - Here's Why...

SELLAS Life Sciences Stock Is Surging Higher: What's Going On?

SELLAS Life Sciences Group climbs higher after a premarket drop, reversing course as investors seem to react to new trial related updates.read more...

<ul class="summary-bullets"><li>As of December 26, 72 deaths have occurred, the company said on Monday.</li><li>SELLAS had said in August that it expects the 80 events to occur by year-end.&nbsp;</li><li>GPS is SELLAS’ lead candidate licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types.</li></ul>Shares of SELLAS Life Sciences Group, Inc. (SLS) traded 17% higher on Monday after the company said that it is approaching the final analysis of its late-stage trial in Acute Myeloid Leukemia. &nbsp;The company is currently evaluating Galinpepimut-S (GPS) as a potential maintenance therapy in patients with Acute Myeloid Leukemia who have achieved complete remission following second-line salvage therapy. AML is a fast-growing cancer of the blood and bone marrow where immature white blood cells build up, crowding out healthy cells, leading to fatigue, infections, and bleeding. GPS is SELLAS’ lead candidate licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types.<h2 class="st-heading-2">Final Analysis Nears</h2>The ongoing GPS trial is an overall survival study and final analysis is expected once 80 deaths have occurred. As of December 26, 72 deaths have occurred, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.sellaslifesciences.com/news/News-Details/2025/SELLAS-Life-Sciences-Provides-Update-on-Pivotal-Phase-3-REGAL-Trial-of-Galinpepimut-S-GPS-in-Acute-Myeloid-Leukemia-AML/default.aspx">said</a> on Monday. SELLAS had said in August that it expects the 80 events to occur by year-end.“We appreciate the continued dedication of the patients, families, and investigators participating in the pivotal Phase 3 REGAL trial where survival times, fortunately for patients and caregivers, appear longer than expected,” said SELLAS CEO Angelos Stergiou. “While the 80th event has not yet occurred, and we remain fully blinded, every passing month may increase the probability of a successful study as highlighted by key opinion leaders in our recent R&amp;D event. Conclusive data will follow the unblinding and analyses of the study results.”<h2 class="st-heading-2">Interim Analysis</h2>In August, an Independent Data Monitoring Committee completed a pre-specified analysis of the trial and issued a positive recommendation to continue the trial without modification. No safety concerns were identified, and available efficacy data were consistent with expectations for continued trial conduct, the company then said.The study completed enrollment in April 2024, with a total of 126 patients randomized.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around SLS stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.A Stocktwits user called the current price “absurd” and opined the stock is worth double digits. “Right this second! Not tomorrow, not next week, not a year from now but immediately right this very second…DOUBLE DIGITS!,” they wrote.<stembedurl>https://www.stocktwits.com/Mr_Anderson007/message/640327741</stembedurl><a href="https://stocktwits.com/symbol/SLS">SLS stock</a> has more than tripled this year and risen by about 239% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/tonix-pharmaceuticals-to-meet-with-fda-in-2026-to-advance-experimental-lyme-disease-prevention-drug/cL75CPSRExm">Tonix Pharmaceuticals To Meet With FDA In 2026 To Advance Experimental Lyme Disease Prevention Drug</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

SELLAS Life Sciences Group Stock Soars As It Nears Final Analysis In Cancer Study

The ongoing GPS trial is an overall survival study and final analysis is expected once 80 deaths have occurred.

How Is The Market Feeling About SELLAS Life Sciences Group Inc?

<ul class="summary-bullets"><li>SELLAS released positive results from its Phase 2 clinical trial for an investigational leukemia drug in early December.&nbsp;</li><li>The company is also expected to release the final event-driven analysis for its galinpepimut-S (GPS) drug by the end of 2025.&nbsp;</li><li>Some retail investors anticipate a buyout or partnership in the near future based on its oncology drug pipeline.</li></ul>SELLAS Life Sciences Group, Inc. (SLS) stock has been on investors’ radar over the past few weeks after the company released positive results from its Phase 2 clinical trial for an investigational leukemia drug in early December.Shares of SLS are up over 78% in just a month and continue to rise as investors discuss the potential of the drug, forthcoming developments, and possibilities of an acquisition. The stock is up nearly 3% in Wednesday’s premarket trade at the time of writing.<h2 class="st-heading-2">Trial Updates</h2>The trial for the SLS009 drug involved combining it with azacitidine (AZA) and venetoclax (VEN) in patients diagnosed with relapsed or refractory acute myeloid leukemia with myelodysplastic-related changes (AML-MR).Patients in the study with limited prior treatment achieved a median overall survival of 8.9 months, outperforming the historical benchmark of approximately 2.5 months for this patient population. Results showed a 46% overall response rate across all participants and a 58% overall response rate in patients with one prior line of therapy.SELLAS said it plans to expand the study of SLS009 in combination with azacitidine and venetoclax among acute myeloid leukemia patients in the first quarter of 2026.Apart from these positive trial results, users are also anticipating more information about the company’s galinpepimut-S (GPS) drug. Earlier this year, SELLAS had said that it expects the final event-driven analysis for the drug to be completed and reported by the end of 2025.<h2 class="st-heading-2">What Are Stocktwits Users Saying?</h2>On Stocktwits, retail sentiment around SLS stock has remained in the ‘bullish’ territory for over a week, and message volume stayed at ‘high’ levels. The volume of retail messages for the stock has jumped 680% in the past month.Apart from the drug discussions, users are also actively discussing the possibility of an acquisition.One user pointed to the potential for a buyout or partnership, citing recent examples such as Cidara Therapeutics, which was bought by Merck for $9.2 billion.<stembedurl>https://stocktwits.com/DSCallez/message/640053184</stembedurl>Another bullish user echoed the sentiment, saying they were looking past trial success and focusing instead on who the buyer could be.<stembedurl>https://stocktwits.com/Johnmtnb2018/message/640055860</stembedurl>A third user said that even if the company did not provide updates on the GPS drug by the end of the year, it was still performing better than anyone expected, and a longer wait would mean a higher buyout price.<stembedurl>https://stocktwits.com/BobWayne/message/640054317</stembedurl><a href="https://stocktwits.com/symbol/SLS">Shares of SLS</a> are up over 197% in the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Researcher performing microbiology separator for PCR diagnosis test in pathology laboratory. 

SLS Stock Has Risen 78% In A Month — What’s The Retail Buzz About?

SLS Stock- Retail investors are actively discussing recent clinical trials and the potential for a buyout or takeover. 

Retail investors are actively discussing recent clinical trials and the potential for a buyout or takeover. 


SELLAS Life Sciences Group Sees Unusually High Options Volume (NASDAQ:SLS)

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Get Free Report) was the target of unusually large options trading activity on Friday. Stock traders acquired 21,865 call options on the stock. This is...

<ul class="summary-bullets"><li>REGAL is a Phase 3 randomized study testing GPS in AML patients who reached complete remission after a second round of rescue treatment.</li><li>The main goal of the trial is to see whether the treatment helps patients live longer overall.</li><li>Phase 2 of the SLS009 clinical trial found that among AML patients who received exactly one earlier line of treatment, the overall response rate climbed to 58%.</li></ul>SELLAS Life Sciences Group, Inc. (SLS) stock has been drawing continued attention as investors are optimistic about the company’s potential following its positive results in acute myeloid leukemia (AML) treatment.&nbsp;The results from the company’s Phase 2 clinical trial for the investigational drug SLS009 in patients with relapsed or refractory AML with myelodysplastic-related changes (AML-MR) and the Phase 3 REGAL trial, a survival-driven study of galinpepimut-S (GPS), are garnering interest.&nbsp;<h2 class="st-heading-2">What Are Stocktwits Users Saying?</h2><a href="https://stocktwits.com/symbol/SLS">SELLAS Life Sciences’ stock</a> inched 0.9% higher in Wednesday’s premarket. On Stocktwits, retail sentiment around the stock remained in ‘bullish’ territory amid ‘high’ message volume levels.&nbsp;A Stocktwits user said if GPS actually works, it will completely change the game, referring to the REGAL trial.<stembedurl>https://stocktwits.com/newTrader9999/message/639398804</stembedurl>Another user said the biggest clear advantage is that combining GPS with SLS009 could lengthen the life cycle of the standard of care to AML patients by many months or even years.<stembedurl>https://stocktwits.com/stockforce123/message/639395388</stembedurl><h2 class="st-heading-2">What Is Phase 3 REGAL Trial</h2>REGAL is a Phase 3 randomized study testing GPS in AML patients who reached complete remission after a second round of rescue treatment (CR2 patients). The main goal of the trial is to see whether the treatment helps patients live longer overall.The final review will begin after 80 events, meaning patient deaths, have taken place, which will help clarify how effective GPS may be for AML patients. At the moment, that number had not yet been met.Phase 2 of the SLS009 clinical trial found that among AML patients who received exactly one earlier line of treatment, the overall response rate climbed to 58%SLS stock has gained over 111% in 2025 and over 150% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-azi-stock-surge-today/cLeJ029REp3">Why Did AZI Stock Surge Over 12% Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Senior scientist Zhou Han sets up a quantitative PCR (polymerase chain reaction).

SELLAS Life Sciences Stock Has Doubled This Year – Here’s Why Retail Investors Are Still Bullish 

The results from the company’s Phase 2 clinical trial for the investigational drug SLS009 and the Phase 3 REGAL trial, a survival-driven study of galinpepimut-S (GPS), are garnering interest.

<ul class="summary-bullets"><li>SELLAS’s Phase 2 clinical trial for its investigational drug SLS009 for acute myeloid leukemia showed positive results.&nbsp;</li><li>Across the treated group, the overall response rate (ORR) reached 46%.</li><li>For the cohort with exactly one earlier line of treatment, the ORR climbed to 58%.</li></ul>SELLAS Life Sciences Group, Inc. (SLS) stock came into the spotlight on Monday morning after encouraging results from its Phase 2 clinical trial for its investigational drug SLS009.&nbsp;The trial involved combining SLS009 with azacitidine (AZA) and venetoclax (VEN) in patients with relapsed or refractory acute myeloid leukemia with myelodysplastic-related changes (AML-MR).<h2 class="st-heading-2">What Did Stocktwits Users Say?&nbsp;</h2><a href="https://stocktwits.com/symbol/SLS">SELLAS’ stock</a> traded over 8% higher in Monday’s premarket. On Stocktwits, retail sentiment around the stock improved to ‘extremely bullish’ from ‘bullish’ the previous day amid ‘high’ message volume.&nbsp;<figure class="image"><img style="aspect-ratio:936/108;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_08_050240_png_2fc0723d0f.webp" alt="SLS’s Sentiment Meter and Message Volume as of 05:00 p.m. ET on Dec. 8, 2025 | Source: Stocktwits" width="936" height="108"><figcaption>SLS’s Sentiment Meter and Message Volume as of 05:00 a.m. ET on Dec. 8, 2025 | Source: Stocktwits</figcaption></figure>A Bullish Stocktwits user said there are many situations where Galinpepimut-S (GPS)and SLS009 can be used alongside venetoclax and azacitidine, creating a powerful multi-drug approach to wipe out AML.<stembedurl>https://stocktwits.com/Juhanialainen/message/638454494</stembedurl>GPS, SELLAS’ lead product candidate, is an immunotherapeutic that targets the Wilms Tumor 1 (WT1) protein.Another user said they always prefer late-stage biotechs to have at least one more solid product or indication in development.<stembedurl>https://stocktwits.com/Sawnchey/message/638460062</stembedurl><h2 class="st-heading-2">Encouraging Response Rates</h2>In the study, 35 evaluable individuals, most with high-risk disease marked by adverse-risk genetics, received SLS009 intravenously at 30 mg twice weekly, alongside AZA/VEN.Across the treated group, the overall response rate (ORR), including complete remission (CR), complete remission with incomplete hematologic recovery (CRi), and morphologic leukemia-free state (MLFS), reached 46%.Patients who had received minimal prior therapy experienced a median overall survival (mOS) of 8.9 months, far exceeding historical survival expectations of roughly 2.5 months in this patient subgroup. For the cohort with exactly one earlier line of treatment, the ORR climbed to 58%.SLS stock has gained over 67% year-to-date.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-ibm-may-want-confluent-3-charts-reveal-ai-play-s-promise/cLIYjkHREll">Why IBM May Want Confluent So Badly: 3 Charts Reveal AI Play's Promise</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

SELLAS Life Sciences Draws Retail Buzz On SLS009 Trial Momentum – Stock Soars In Pre-Market

The trial involved combining SLS009 with azacitidine and venetoclax in patients with relapsed or refractory acute myeloid leukemia.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Traders are looking ahead to 2026 with immense optimism, anticipating substantial gains and celebrating it as a pivotal year for investors.

Executive leadership faces harsh criticism and accusations of misrepresenting timelines and scamming retail investors.

SLS
SELLAS Life Sciences Group Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SLS News

SLSSELLAS Life Sciences Group Inc